Triggering of the complement cascade induces tumor cell lysis via complement-dependent cytotoxicity (CDC) and attracts and activates cytotoxic cells. It therefore represents an attractive mechanism for mAb in cancer immunotherapy development. The classical complement pathway is initiated by IgG molecules that have assembled into ordered hexamers after binding their Ag on the tumor cell surface. The requirements for CDC are further impacted by factors such as Ab epitope, valency, and affinity. Thus, mAb against well-validated solid tumor targets, such as the epidermal growth factor receptor (EGFR) that effectively induces complement activation and CDC, are highly sought after. The potency of complement activation by IgG Abs can be increased via several strategies. We identified single-point mutations in the Fc domain (e.g., E345K or E430G) enhancing Fc:Fc interactions, hexamer formation, and CDC after Ab binds cell-surface Ag. We show that EGFR Abs directed against clinically relevant epitopes can be converted into mAb with unprecedented CDC activity. Alternative strategies rely on increasing the affinity of monomeric IgG for C1q by introduction of a quadruple mutation at the C1q binding site or via generation of an IgG1/IgG3 chimera. In this study we show that selective enhancement of C1q binding via avidity modulation is superior to the unattended increase in C1q binding via affinity approaches, particularly for target cells with reduced EGFR expression levels. Improving Fc:Fc interactions of Ag-bound IgG therefore represents a highly promising and novel approach for potentiating the anti-tumor activity of therapeutic mAb against EGFR and potentially other tumor targets.
Introduction: Activation of complement (C) constitutes an important effector mechanism of monoclonal antibodies in cancer therapy. Unmodified IgG1 antibodies against the epidermal growth factor receptor (EGFR), a well-validated tumor target, lack the capacity to induce complement-dependent cytotoxicity (CDC) as single agents. Recently, significantly improved CDC was demonstrated after antigen-bound IgG molecules formed hexameric structures through intermolecular Fc-Fc contacts. Single point mutations (E345K or E430G) that enhance hexamerization of IgG molecules conditional on antigen binding have been identified to represent a platform for enhanced C activation (Diebolder et al Science 343:1260, 2014, de Jong et al, PLOS Biology, in press). Alternative strategies to enhance CDC have focused on enhancing C1q binding via affinity-maturation of the C1q binding site (S239D/H268F/S324T/I332E; DFTE) or by generating IgG1/IgG3 isotype chimeras (113F). The aim of the present study was to investigate whether EGFR antibodies optimized for each of these approaches differed in terms of CDC activity. Methods: EGFR antibodies comprising engineered Fc domains that carry mutations to enhance hexamerization (E345K or E430G), or increase C1q affinity (DFTE), or that exist of IgG1/IgG3 chimeras (113F) were constructed. CDC activity was assessed by 51Cr release assays in the presence of human serum. Antibody mediated C1q binding or C4b deposition on tumor cells was analyzed by flow cytometry. Apparent C1q binding affinity was determined by C1q specific ELISA. Results: Here, we demonstrate that affinity maturation of the C1q binding site (DFTE & 113F) increased C1q binding in the absence of antigen, whereas mutations that enhance Fc-Fc interactions (E345K & E430G), and so enhance hexamerization after target binding, did not. However, these latter mutations strongly increased C1q avidity and CDC for EGFR antibodies bound to cells. Notably, the latter strategy translated in superior CDC activity, which was particularly evident for tumor cells with low EGFR expression levels. Furthermore, hexamerization enhanced CDC was particularly sensitive to peptides inhibiting Fc-Fc interactions, supporting their different mode of action compared to other CDC-enhancing strategies. Interestingly, also the EGFR epitope recognized by different antibodies impacted on the CDC activity. Conclusion: Enhancement of hexamer formation by EGFR antibodies conditional on antigen binding is a promising novel approach to improve their anti-tumor activity. Strategies that enhanced complement binding independent of antigen engagement by the antibody appeared less effective. Citation Format: Annalina Tammen, Frank J. Beurskens, Stefanie Derer, Ralf Schwanbeck, Paul W.H.I. Parren, Janine Schuurman, Thomas Valerius. Potent complement-dependent cytotoxicity of tumor cells by target bound hexamerization of EGFR antibodies. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 578.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.